Nanoparticle-formulated drug combination is effective in medulloblastoma, a pediatric brain tumor

Researchers have demonstrated that a novel combination of two drugs that act as targeted inhibitors, delivered in a nanoparticle formulation, extend the survival of mice with medulloblastoma. The research team believes this laboratory success could be translated into a less toxic treatment for medulloblastoma, the most common malignant pediatric brain tumor.

Frozen testicular tissue still viable after two decades

Study identifies potential target for treating childhood blood cancer

RAI Treatment in DTC Survivors Associated With Increased Risk of Other Cancers

AYA cancer survivors at higher risk for death due to second primary cancers

Immunotherapy for kids: An option for childhood liver cancer?

Biological pathways found that drive genomic changes and bone metastasis in Ewing Sarcoma

Research reveals a therapeutic opportunity to prevent rhabdomyosarcoma recurrence

We may know why some childhood cancers resolve on their own

Study finds jumping 'junk' DNA is a novel cause of childhood brain cancer

Cardiovascular care of pediatric cancer survivors: Mitigating a lifelong risk

Recent Posts